Intravenous Iron Supplementation (Ferric Carboxymaltose)
Iron deficiency is now recognized in 2026 as a major driver of heart failure fatigue and hospitalisation. NICE guidelines now mandate screening for iron deficiency in all HF patients.
If ferritin levels are low, patients are treated with Intravenous Ferric Carboxymaltose. Clinical evidence in 2026 shows that correcting iron levels via IV (rather than oral tablets, which are poorly absorbed in HF) significantly improves exercise capacity and quality of life while reducing the risk of heart failure readmission.
1 View